<DOC>
	<DOCNO>NCT02723942</DOCNO>
	<brief_summary>The purpose study preliminarily evaluate safety efficacy CAR-T cell immunotherapy GPC3 positive hepatocellular carcinoma .</brief_summary>
	<brief_title>CAR-T Cell Immunotherapy HCC Targeting GPC3</brief_title>
	<detailed_description>Chimeric antigen receptor ( CAR ) recombinant receptor antigen-binding T cell activate function . Chimeric antigen receptor T cell Immunotherapy advantage compare conventional immunotherapy , especially deal patient hematologic malignancy solid malignant tumors.This study design novel specific Chimeric antigen receptor target glypican-3 ( GPC3 ) antigen.After CAR-T cell infusion , At periodic interval , investigator evaluate clinical symptom Improved condition disease.Through study , investigator evaluate safety efficacy CAR-T cell immunotherapy treat GPC3 positive malignant glioma patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Age:1870 year . 2 . Gender : . 3 . GPC3 high expression hepatocellular carcinoma patient . 4 . Non diffuse hepatocellular carcinoma，no extrahepatic metastasis portal vein vascular invasion . 5 . Degree liver cirrhosis：class A class B 7 accord Childpuge grade standard . 6 . Routine blood test：white blood cell count（WBC ) &gt; =3×10^9/L , Lymphocyte percentage &gt; =15 % , hemoglobinHbo（Hb） &gt; =90g/L , prothrombin time（PT） prolongation &lt; =50 % normal value , Cluster differentiation 3 ( CD3 ) positive T cell count &gt; =0.8×10^9/L . 7 . Liver Pancreatic function：Alanine aminotransferase/Aspartate transaminase ( ALT/AST ) &lt; =5 time normal value , total bilirubin ( TBiL ) &lt; =3.0mg/dL , albumin ( ALB ) &gt; =35g/L , prothrombin time ( PT ) : International Normalized Ratio ( INR ) &lt; =1.7 prothrombin time ( PT ) prolongation &lt; =4s , Serum lipase &lt; =1.5 time normal value , Serum amylase &lt; =1.5 time normal value . 8 . Renal function：Serum creatinine ( SCr ) &lt; =221μmol/L ( 2.5mg/L ) . 9 . Karnofsky Performance Status ( KPS ) &gt; =60；Expected survival time &gt; =12 week . 10 . Peripheral venous access ；no contraindication lymphocyte separation . 11 . No serious complication . 12 . Voluntarily sign informed consent . 1 . Pregnant lactating woman . 2 . Lymphocyte separation peripheral venous access perform patient . 3 . Patients active stage infection coagulation disorder . 4 . Patients previous history hepatic coma . 5 . Patients severe gastrointestinal ulcer gastrointestinal bleeding . 6 . Patients organ transplantation wait organ transplantation . 7 . Patients anticoagulant therapy . 8 . Patients antiplatelet therapy . 9 . Serum sodium ( Na ) &lt; 125 mmol/L . 10 . Serum potassium ( K ) &lt; 3.5 mmol/L ( except patient standard use supplement ) . 11 . Patients organ failure： 1. cardiac function：level three accord New York Heart Association ( NYHA ) criterion . 2. liver function : class C accord Childpuge grade standard . 3. renal function : Chronic kidney disease ( CKD ) phase 4 ; renal insufficiency phase Ⅲ . 4. pulmonary function：severe respiratory failure symptom , involve organ . 5 . Brain function : central nervous system abnormality disturbance consciousness . 12 . Patients non control infectious disease , example , HIV positive , syphilis , hepatitis A , hepatitis B , hepatitis C , hepatitis E virus ( HEV ) positive etc . 13 . Patients used corticosteroid immunosuppressive agent past 4 week . 14 . Patients autoimmune disease . 15 . Patients previous history gene therapy . 16 . The actual transfection rate T cell low 30 % proliferation le 5 time costimulation . 17 . Patients participate drug trial past 4 week . 18 . Patients receive radiation treatment past 4 week . 19 . Patients meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>glypican-3 ( GPC3 )</keyword>
	<keyword>chimeric antigen receptor-modified T cell ( CAR-T )</keyword>
	<keyword>hepatocellular carcinoma ( HCC )</keyword>
</DOC>